Financial Wire

Geopolitics, Beijing Regulatory Changes Lift Asian Stock Markets

-- Asian stock markets tracked north on Monday, as traders weighed pending Tehran-Washington negotiations regarding the Persian Gulf, and revamped securities-industry rules issued late Friday in Beijing.

Hong Kong, Shanghai and Tokyo finished in green, as did most other regional exchanges.

In Japan, the Nikkei 225 opened higher and held ground, finishing up 0.6% as traders mulled the outlook for US and Iranian negotiations this week in Pakistan.

The benchmark Nikkei 225 rose 348.99 to 58,824.89, as gaining issues outnumbered losers 123 to 98.

Leading the upside was Renesas Electronics, up 6.4%, while Sumitomo Pharma declined 5.9%.

In Hong Kong, the Hang Seng Index opened evenly and gained in trading, closing up 0.8% on investor acceptance of securities-industry rules changes in China.

The broad gauge Hang Seng rose 200.74 to 26,361.07 as gaining issues outnumbered losers 61 to 28. The Hang Seng TECH Index gained 0.5% on the day, while the Mainland Properties Index rose 0.3%.

Leading the upside was Xinyi Solar, gaining 6.2%, while PetroChina declined 3.3%.

On the mainland, the Shanghai Composite rose 0.8% to 4,082.13.

In industry news, the China Securities Regulatory Commission (CSRC) and other authorities late Friday announced changes to regulations to strengthen market supervision and attract long-term investment.

In general, the new rules ease investment by "strategic investors," or institutional money, into Chinese public companies, particularly into the powerful, voting "A-share" class, but also tighten rules on the illegal selling of shares, and the practice of "auditor shopping" for accounting services.

On the other regional exchanges, the S. Korean KOSPI rose 0.4%; the Taiwan TWSE inclined 0.4%; the Australian ASX 200 inclined 0.1%; the Singapore Straits Times Index rose 0.1%, and the Thai Set was steady. In late trading in Mumbai, the Sensex was down 0.1%

The MSCI All Country Asia Pacific Index rose 0.3% on the day.

Related Articles

Mining & Metals

New Found Gold Up In US Premarket As Announces $205M Funding Package to Advance Queensway Project

New Found Gold (NFG.V) was at last look up 1.6% in US Premarket trade Monday after announcing a $205 million finance package made up of a $100 million bought deal shares financing with lead orders from EdgePoint Investment Group and cornerstone investor Eric Sprott and a $105 million senior secured credit facility with EdgePoint.In a statement it said proceeds will be used to advance the Queensway gold project in Newfoundland.The company will issue 33.8 million shares at $2.96 each, to raise $100 million. The underwriters have also been granted a 15% over-allotment option.New Found Gold has also sealed a deal with EdgePoint for a secured credit facility of up to $105 million. The funds will be advanced in two tranches: $70 million and $35 million. Both tranches will be released when certain conditions are met.In return, New Found Gold will issue non-transferable share purchase warrants to EdgePoint totalling US$9 million: US$6 million worth of warrants will be issued on Tranche 1, which will be exercisable for 2.5 million shares at $3.30 each. The Tranche 2 warrants, totalling US$3 million will be exercisable for shares at a price equal to a 25% premium to the closing price of the shares on the TSX Venture immediately before the Tranche 2 funding date.New Found Gold says the $205 million funding package covers the initial capital expenditures required to bring its flagship Queensway Gold Project-Phase I into production. It added that it will not proceed with the US$75 million secured loan facility and warrants issue with Nebari Natural Resources Credit Fund II, announced in early March.New Found Gold closed up $0.09 or 3.1% to $2.96, on the TSX Venture Exchange on Friday.

$NFG.V$SII.TO
Treasury

Brief: Canada's CPI at 2.4% Y/Y in March; Scotiabank Says Consensus Saw at 2.6% Y/Y

$^GSPTSE$.GSPTSE$$CXY
Asia

CSPC Pharma Unit's Tumor Drug Reaches Primary Efficacy Endpoint

CSPC Pharmaceutical (HKG:1093) said the phase Ib/III clinical study of Sirolimus for Injection (Albumin-bound) met its pre-specified primary efficacy endpoint, showing statistically significant differences and clear clinical benefits, according to a Monday Hong Kong bourse filing.The drug was developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang), a unit of the company for the treatment of advanced malignant perivascular epithelioid cell tumour.

$HKG:1093